Our Strategy and Executive Partners have acquired a wealth of knowledge through their extensive pharma experience. We are available to offer insight on a variety of critical issues facing the drug market today.  Contact us to schedule an interview with a member of our leadership team or to request a comment on an industry issue.

Leadership Team & Expertise

  • Subbarao Jayanthi: Corporate Strategy, Life Cycle Management, Mergers and Acquisitions, Biosimilars, Co-Promotion Effectiveness 
  • Rich Tinsley: Gene Therapies, Strategy, Commercialization, Life Cycle Management, Forecast Modeling
  • Jim Hoyes: Corporate Development, Global Operations, Commercialization, Licensing, Mergers and Acquisitions, Co-Promotion Effectiveness 
  • Frank Koos: Pharmaceutical Marketing, Business Development, Sales Force Leadership, High Value B2B, Strategic Account Management, Team Structure 
  • Nick DeSanctis: New Product Planning, Portfolio Management, Life Cycle Management, Target Value Profile,  Therapeutic Area Strategy
  • Jose De Leon: New Product Planning, Early Commercialization, Global Product Launch, Global Product Marketing, Life Cycle Management, Global Strategic Planning
  • Philip Vorhies: New Product Strategy, Commercial Excellence, Product Launch Strategy, Brand and Portfolio Strategy, Life Cycle Planning
  • Bradley Kozar: Payer Strategy, Market Access, Commercial Managed Care, Pharmacy Benefit Managers, Health Exchanges, Accountable Care Organizations, Long Term Care/Home Health, Government Healthcare (i.e. Medicare Part D, Medicaid, VAs/Tricare)
RxC Therapeutic Focus Areas

Therapeutic Focus Areas

  • Specialty Biopharma
  • Oncology
  • Rare Diseases
  • Vaccines
  • Biosimilars
  • Gene Therapies

Sample Questions

  • What is the outlook for a second or third entry into the biosimilars market?
  • How will recent approval of the first gene therapy in the United States impact future gene therapies?
  • What pricing hurdles do gene therapy treatments need to overcome?